Dr. Xingli Wang

It's more like, I normally call it ABC, the Chinese-born American, because the CEOs, half of the team are based in the US.

And we are, as Fusang, a local-grown, China-local-grown pharmaceutical companies.

We need to go the similar pattern ways as companies like Takeda in Japan several decades ago, but we are only going to go a little faster.

So my confidence is in five to 10 years, we will be noted.

I wouldn't be so ambitious that we're going to be ranked the top, whatever, 20, 30 or 50, but at least we'll be noted as one of the major players in oncology field.

And hopefully in the autoimmune disease, if we do come across with a good product.

But oncology will certainly will be noted.

Sure, obviously.

Maybe the number you obtained might be slightly different from the source we always have.

Our current investment on the R&D is about, this morning we just reviewed it, around 13%.

Our goal is actually to have a stepwise increase every year, about, you know, 1 to 2% every year.

So in kind of like on the top side, maybe anywhere between 16 to 20%, when we see how we go, that's 20% will be our ultimate goal to be part of it.

And this is the holding or the total understanding from every level of the management, from the top to mid-level management.

Everybody knows this is our direction, this is our commitment.

So, you know, if you want to live big, you have to invest.

I mean, if you see the history of all the pharmaceuticals, the linear relationship between investment and products outcome and the revenue is even though there are big variations, but in general, there's a linear relationship.

No, I mean, everybody has this different source of the numbers.

Yes.

Yeah.

I mean, if you know the history of the PD-1 inhibitors, I mean, there are plenty of them around.